Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow‐up study

Kantor, Elizabeth D.; Zhang, Xuehong; Wu, Kana; Signorello, Lisa B.; Chan, Andrew T.; Fuchs, Charles S.; Giovannucci, Edward

doi:10.1002/ijc.30250

Cited by 34 publications

(36 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…41 Also, several studies have reported a risk reduction of CRC associated with their use. [17][18][19][20][21] These drugs have been reported to inhibit the production of some inflammatory mediators such as NF-kB, 15 In fact, a recently published study 17 reported a protective effect against CRC among users of SYSADOAs but the adjustment for NSAID use led to a loss of statistical significance, which is consistent with our results.…”

Section: Controlssupporting

confidence: 89%

“…Although, the clinical utility of these drugs has been a matter of controversy, in recent randomised clinical trials they have shown to be as effective as celecoxib and superior to placebo . Also, several studies have reported a risk reduction of CRC associated with their use . These drugs have been reported to inhibit the production of some inflammatory mediators such as NF‐kB, a cell transcription factor capable to upregulate COX‐2 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Population‐based case‐control study: chemoprotection of colorectal cancer with non‐aspirin nonsteroidal anti‐inflammatory drugs and other drugs for pain control

Rodríguez‐Miguel

Rodrı́guez

Gil

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Inflammation and overexpression of cyclooxygenase‐2 (COX‐2) have been described to play a key role in the progression from nonpathologic intestinal mucosa to colorectal cancer (CRC). Aims To assess the chemoprotective effect of non‐aspirin nonsteroidal anti‐inflammatory drugs (NA‐NSAIDs) under different patterns of use in a Mediterranean population and to explore the potential effect of symptomatic slow‐acting drugs for osteoarthritis (SYSADOAs; chondroitin sulfate and glucosamine) and metamizole (or dipyrone), also reported to influence COX‐2 activity. Methods We performed a case‐control study nested in a cohort extracted from the primary care database, BIFAP. From 2001 to 2014, we included 15 491 incident cases and 60 000 random controls. To estimate the association between the drugs of interest and CRC, we built logistic regression models to compute the adjusted‐odds ratios (AOR) and 95% confidence intervals (CI). Results NA‐NSAIDs use was associated with a reduced risk of CRC (AOR = 0.67; 95% CI: 0.63‐0.71) and increased linearly with duration of treatment (p for trend <0.001). The effect diminished upon discontinuation but persisted statistically significant up to 1 year. All individual NA‐NSAIDs examined showed a decreased risk. The concomitant use of proton‐pump inhibitors (PPI) had no impact on the protective effect of NA‐NSAIDs; AORPPI + NSAID = 0.64; 0.58‐0.71. SYSADOA use was associated with a reduced risk (0.79; 0.69‐0.90) but disappeared after the exclusion of NSAID users during the previous 1 or 3 years (0.85; 0.70‐1.04 and 1.00; 0.76‐1.31 respectively). Metamizole did not show a chemoprotective effect. Conclusions NA‐NSAID use is associated with a duration‐dependent risk reduction of CRC not shared by SYSADOAs or metamizole.

show abstract

Section: Controlssupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Population‐based case‐control study: chemoprotection of colorectal cancer with non‐aspirin nonsteroidal anti‐inflammatory drugs and other drugs for pain control

Rodríguez‐Miguel

Rodrı́guez

Gil

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Besides the purported impact on OA, there is growing evidence to suggest beneficial effects of G&C use on other inflammation-associated health conditions, including reduced risk of CRC, and possibly cardiovascular disease [3,4,[25][26][27]. Some of these associations may be linked to microbial metabolism of G&C that leads to reduced systemic inflammation or production of metabolites that alter other signaling pathways in the host.…”

Section: Discussionmentioning

confidence: 99%

“…Typically combined and taken together as a single pill, G&C are commonly used for joint-related osteoarthritis (OA) pain. More recently, several large, prospective cohort studies have shown that use of G and/or C are associated with a reduction in colorectal cancer (CRC) risk [2][3][4][5]. Administration of G has also been shown to improve inflammatory bowel disease in both animal models [6] and humans [7], and the combination of G&C reduced systemic inflammation in a small trial of healthy adults [8].…”

Section: Introductionmentioning

confidence: 99%

Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans

et al. 2019

View full text Add to dashboard Cite

Glucosamine and chondroitin (G&C), typically taken for joint pain, are among the most frequently used specialty supplements by US adults. More recently, G&C have been associated with lower incidence of colorectal cancer in human observational studies and reduced severity of experimentally-induced ulcerative colitis in rodents. However, little is known about their effects on colon-related physiology. G&C are poorly absorbed and therefore metabolized by gut microbiota. G&C have been associated with changes in microbial structure, which may alter host response. We conducted a randomized, double-blind, placebo-controlled crossover trial in ten healthy adults to evaluate the effects of a common dose of G&C compared to placebo for 14 days on gut microbial community structure, measured by 16S rRNA gene sequencing. Linear mixed models were used to evaluate the effect of G&C compared to placebo on fecal microbial alpha and beta diversity, seven phyla, and 137 genera. Nine genera were significantly different between interventions (False Discovery Rate < 0.05). Abundances of four Lachnospiraceae genera, two Prevotellaceae genera, and Desulfovibrio were increased after G&C compared to placebo, while Bifidobacterium and a member of the Christensenellaceae family were decreased. Our results suggest that G&C affect the composition of the gut microbiome which may have implications for therapeutic efficacy.

show abstract

“…3 4 Although the effectiveness of glucosamine supplementation for osteoarthritis and joint pain remains controversial, 1 5 several human, animal and laboratory studies have suggested that glucosamine may have anti-inflammatory properties, [6][7][8] which could decrease the risk of multiple diseases. [9][10][11] In this context, several recent epidemiological investigations indicated that glucosamine use might play a role in prevention of cancer, [12][13][14] cardiovascular disease (CVD) 15 and other diseases. 16 17 Nonetheless, only a few studies 15 18 19 have evaluated the associations between glucosamine use and mortality outcomes, especially for cause-specific mortality.…”

Section: Introductionmentioning

confidence: 99%

Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study

Gao

Chung

et al. 2020

Ann Rheum Dis

View full text Add to dashboard Cite

Objectives To evaluate the associations of regular glucosamine use with all-cause and cause-specific mortality in a large prospective cohort. Methods This population-based prospective cohort study included 495 077 women and men (mean (sd) age, 56.6 (8.1) years) from the UK Biobank study. participants were recruited from 2006 to 2010 and were followed up through 2018. We evaluated all-cause mortality and mortality due to cardiovascular disease (cVd), cancer, respiratory and digestive disease. HRs and 95% cis for all-cause and cause-specific mortality were calculated using cox proportional hazards models with adjustment for potential confounding variables. results at baseline, 19.1% of the participants reported regular use of glucosamine supplements. during a median follow-up of 8.9 years (iQR 8.3-9.7 years), 19 882 all-cause deaths were recorded, including 3802 cVd deaths, 8090 cancer deaths, 3380 respiratory disease deaths and 1061 digestive disease deaths. in multivariable adjusted analyses, the HRs associated with glucosamine use were 0.85 (95% ci 0.82 to 0.89) for all-cause mortality, 0.82 (95% ci 0.74 to 0.90) for cVd mortality, 0.94 (95% ci 0.88 to 0.99) for cancer mortality, 0.73 (95% ci 0.66 to 0.81) for respiratory mortality and 0.74 (95% ci 0.62 to 0.90) for digestive mortality. The inverse associations of glucosamine use with all-cause mortality seemed to be somewhat stronger among current than non-current smokers (p for interaction=0.00080). Conclusions Regular glucosamine supplementation was associated with lower mortality due to all causes, cancer, cVd, respiratory and digestive diseases.on July 9, 2020 by guest. Protected by copyright.

show abstract

Use of glucosamine and chondroitin supplements in relation to risk of colorectal cancer: Results from the Nurses' Health Study and Health Professionals follow‐up study

Cited by 34 publications

References 40 publications

Population‐based case‐control study: chemoprotection of colorectal cancer with non‐aspirin nonsteroidal anti‐inflammatory drugs and other drugs for pain control

Population‐based case‐control study: chemoprotection of colorectal cancer with non‐aspirin nonsteroidal anti‐inflammatory drugs and other drugs for pain control

Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans

Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study

Contact Info

Product

Resources

About